scholarly journals Strengthening Medication Adherence Practices in Chronic Disease Patients-clinical Pharmacist Driven Focused Approach

2019 ◽  
Vol 12 (2) ◽  
pp. 70-76
Author(s):  
Tarun Wadhwa ◽  
Hanin Jalal ◽  
Madlin Merghani ◽  
Aaesha Al Shehhi
2017 ◽  
Vol 6 (1) ◽  
pp. 63 ◽  
Author(s):  
AhmadAli Eslami ◽  
SeydeShahrbanoo Daniali ◽  
FiroozeMostafavi Darani ◽  
Mohammad Mazaheri

2021 ◽  
Vol 10 (36) ◽  
pp. 3171-3177
Author(s):  
Juhi Singh ◽  
Md Shamshir Alam ◽  
Anuj Malik ◽  
Shubham Singh Tyagi ◽  
Mohd Tousib ◽  
...  

Adherence has been defined as the “voluntary, active, and collaborative involvement of the patients in mutually acceptable courses of behaviour to produce desired therapeutic effects”. Medication adherence generally illustrates the term as to whether the patients take their medicines as per prescription instruction and either they keep on to take a prescribed medication. Medication adherence performance has thus been classified into two head conceptions, namely, adherence and persistence. Whilst theoretically similar, adherence refers to concentration of drug utilization for the duration of the ongoing treatment, whereas persistence refers to the general interval of drug therapy. Improving prescription adherence may impact the well-being of the populace than the revelation of any new treatment. Indian patients are not adherent to their medication half the time, mainly due to lack of proper education and patient counselling. Albeit most doctors do not accept adherence basically because of the absence of access or neglect, and no adherence can frequently be a purposeful decision made by the Indian patients. Persistent covering of their medicine taking conduct is regularly persuaded by feelings with respect to both supplier and the patient, prompting possible desperate outcomes. On time medicine taking behaviour of the patients have great impact on the health of people than the need for new treatment option. KEY WORDS Medication Adherence, Drug Therapy, Prescription, Wellbeing, Compliance, Chronic Disease


2016 ◽  
Vol 25 (8) ◽  
pp. 898-907 ◽  
Author(s):  
Melissa L. Santorelli ◽  
Michael B. Steinberg ◽  
Kim M. Hirshfield ◽  
George G. Rhoads ◽  
Elisa V. Bandera ◽  
...  

2019 ◽  
Vol 53 (12) ◽  
pp. 1214-1219 ◽  
Author(s):  
Bruce A. Warden ◽  
Michael D. Shapiro ◽  
Sergio Fazio

Background: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. In response, a multidisciplinary team approach, which includes clinical pharmacists, is recommended to improve patient outcomes. The purpose of the study was to describe interventions associated with integration of a clinical pharmacist, with an emphasis on pharmacist-generated patient cost avoidance. Methods: This is a prospective observational study detailing pharmacist-initiated interventions within an academic preventive cardiology service. Interventions targeting pharmacotherapy optimization, side effect management, patient education, medication adherence, and cost avoidance were implemented during shared office visits with providers and/or on provider consultation for remote follow-up. Tabulation of cost avoidance was arranged into 2 formats: clinical interventions implemented by the pharmacist and direct patient out-of-pocket expense reduction. Money saved per clinical intervention was extrapolated from data previously published. Patient out-of-pocket expense prior to and after pharmacist involvement was calculated to assess aggregate yearly patient cost savings. Results: Over 12 months the pharmacist intervened on 974 patients, totaling 3725 interventions. Cost avoidance strategies resulted in yearly savings of $830 748 in aggregate—$149 566 from clinical interventions and $681 182 from patient out-of-pocket expense reduction. Monthly patient out-of-pocket expense was reduced from a median (interquartile range) of $217 ($83.5-$347) before to $5 ($0-$18) after pharmacist intervention. Conclusions: Addition of a clinical pharmacist within an academic preventive cardiology clinic generated substantial pharmacotherapy interventions, resulting in significant cost avoidance for patients. The resulting cost avoidance may result in improved medication adherence and clinical outcomes.


BMJ Open ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. e037843
Author(s):  
Jennifer Sumner ◽  
Jason Phua ◽  
Yee Wei Lim

IntroductionNovel and efficient healthcare approaches are needed to better serve increasingly older chronic disease patients. Many effective integrated chronic disease management strategies have emerged from the primary care sector. However, in many Asian and developing countries, primary care is underdeveloped, and patients prefer secondary-based services. The Integrated Generalist-led Hospital (IGH) care model is a new approach, which may be better suited for chronic disease patients in the local context.Methods and analysisA hybrid type I study on the effectiveness and implementation of the IGH care model will be conducted. Implementation evaluation will be informed by the Consolidated Framework of Implementation Research (CFIR). Quantitative and qualitative data will be collected through in-depth interviews and focus group discussions with staff, a staff survey, patient interviews, clinical outcomes and cost data. Clinical outcomes include the length of stay, readmission, emergency room visit rate and mortality. Clinical outcomes will be summarised and compared with a propensity-matched ‘usual care’ group (derived from the general medicine ward(s) at a separate hospital). The Kaplan-Meier approach will be used to estimate time until death and time until first readmission (both within 30 days of discharge) and time until discharge. Multivariate regression models will be used to investigate the association between the care model and occurrence of readmission, emergency room visit and death, all within 30 days of discharge. Qualitative data will be analysed using a thematic analysis method. Qualitative and quantitative data will also be coded according to the five domains of the CFIR.Ethics and disseminationThis protocol was reviewed and approved by the National Healthcare Group Domain Specific Review Board (NHG DSRB 2019/00308). Results will be published in peer-reviewed scientific journals and conference presentations. Findings will also be discussed with key stakeholders through local dissemination events.


Author(s):  
Supa Pengpid ◽  
Karl Peltzer

The study aimed to estimate independent and combined associations of sedentary behaviour and physical activity with anxiety and depression among chronic disease patients in Myanmar and Vietnam. The cross-sectional sample included 3201 chronic disease patients (median age 51 years, interquartile range 25) systematically recruited from primary care facilities in 2015. Sedentary time and physical activity were assessed with the General Physical Activity Questionnaire (GPAQ). Overall, the prevalence of sedentary time per day was 51.3% < 4 h, 31.2% between 4 and 8 h, and 17.5% 8 or more hours a day), and 30.7% engaged in low physical activity, 50.0% moderate, and 23.6% high physical activity. The prevalence of anxiety and depression was 12.7% and 19.9%, respectively. In the final logistic regression model, adjusted for relevant confounders, higher sedentary time (≥8 h) did not increase the odds for anxiety or depression, but moderate to high physical activity decreased the odds for anxiety and depression. Combined regression analysis found that participants with both less than eight hours of sedentary time and moderate or high physical activity had significantly lower odds of having anxiety and depression. Findings suggest an independent and combined association between moderate or high physical activity and low sedentary time with anxiety and/or depression among chronic disease patients in Myanmar and Vietnam.


Author(s):  
Elena Grau García ◽  
Jose Ivorra Cortés ◽  
Emilio Monte Boquet ◽  
Cristina Alcañiz Escandell ◽  
Inmaculada Chalmeta Verdejo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document